June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Rational tuning of visual cycle modulator pharmacodynamics
Author Affiliations & Notes
  • Philip Kiser
    Pharmacology, Case Western Reserve University, Pepper Pike, Ohio, United States
    Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States
  • Jianye Zhang
    Pharmacology, Case Western Reserve University, Pepper Pike, Ohio, United States
  • Mohsen Badiee
    Chemistry, CASE WESTERN RESERVE UNIVERSITY, Cleveland, Ohio, United States
  • Gregory Tochtrop
    Chemistry, CASE WESTERN RESERVE UNIVERSITY, Cleveland, Ohio, United States
  • Krzysztof Palczewski
    Pharmacology, Case Western Reserve University, Pepper Pike, Ohio, United States
  • Footnotes
    Commercial Relationships   Philip Kiser, None; Jianye Zhang, None; Mohsen Badiee, None; Gregory Tochtrop, None; Krzysztof Palczewski, None
  • Footnotes
    Support  IK2BX002683 (Dept of Veterans Affairs), R01EY009339 (National Eye Institute)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2970. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Philip Kiser, Jianye Zhang, Mohsen Badiee, Gregory Tochtrop, Krzysztof Palczewski; Rational tuning of visual cycle modulator pharmacodynamics. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2970.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Modulators of the visual cycle have been developed for treatment of various retinal disorders. These agents were designed to inhibit retinoid isomerase RPE65 based on the idea that attenuation of visual pigment regeneration could reduce formation of toxic retinal conjugates. Recently, it was discovered that these agents reversibly form retinal-Schiff base adducts through their primary amine moieties, which also contributes to their retinal protective activity. Inhibition of RPE65 as a therapeutic strategy is complicated by adverse effects resulting from slowed chromophore regeneration whereas effective retinal sequestration can require high doses of drug with potential off-target effects. Here, we employed a structure-based approach to design retinal-sequestering visual cycle modulators with varying degrees of direct retinoid isomerase inhibitory activity.

Methods : RPE65-emixustat/MB-001 crystal structures were used to design primary amine compounds with varying degrees of complementarity to the RPE65 active site. These compounds were synthesized and tested for visual cycle inhibitory activity. In vivo formation of retinal Schiff-base adducts was studied using mass spectrometry. Efficacy in protecting the retina from light damage in Abca4-/-/Rdh8-/- mice was evaluated by OCT. Binding of compounds to the RPE65 active site cavity was studied by x-ray crystallography.

Results : Appropriate substitutions to the emixustat core structure resulted in a series of compounds effectively lacking in vitro retinoid isomerase inhibitory activity, whereas substitutions of the cyclohexyl tail potentiated RPE65 inhibition. Crystal structures of the latter group of compounds in complex with RPE65 confirmed the mechanism of enhanced inhibition. The non-inhibitory derivative series produced discernible visual cycle suppression in vivo, albeit much less potently than emixustat. These agents maintained the capability to distribute into the retina and form Schiff base adducts. Most of the compounds conferred protection against retinal phototoxicity, suggesting that both direct RPE65 inhibition and retinal sequestration are both of therapeutic relevance.

Conclusions : These data support the idea that visual cycle suppression is not essential for the retinal protective effects of primary amine retinoid-mimetic compounds, a finding that has important implications for the use of visual cycle modulators in the treatment of retinal diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×